Big Ten Cancer Research Consortium   Report issue

Academic/Hospital Phase 1 Phase 2
Founded: Indianapolis IN United States (1958)

Organization Overview

First Clinical Trial
2010
NCT01122199
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Al B. Benson, III, MD | Bert O'Neil, MD | Big Ten Cancer Research Consortium | David VanderWeele | H Scott Boswell | Monika Joshi | Oana Danciu, MD | Shadia Jalal | Sherif Farag | Veronika Bachanova

Active Ingredients

Drugs in Phase 2 Trials (41)

abemaciclib (verzenio) (1 trial)

atezolizumab (tecentriq) (4 trials)

bendamustine (treanda) (1 trial)

bevacizumab (avastin) (3 trials)

bicalutamide (casodex) (1 trial)

carboplatin (paraplatin) (3 trials)

ceralasertib (1 trial)

cisplatin (platinol) (2 trials)

darolutamide (Nubeqa) (1 trial)

docetaxel (taxotere) (1 trial)

durvalumab (imfinzi) (4 trials)

etoposide (vepesid) (1 trial)

fluorouracil (efudex) (2 trials)

fulvestrant (faslodex) (1 trial)

gedatolisib (1 trial)

goserelin (zoladex) (1 trial)

guadecitabine (1 trial)

imprime pgg (1 trial)

ipatasertib (1 trial)

ipilimumab (yervoy) (1 trial)

irinotecan (Camptosar) (1 trial)

ixazomib (ninlaro) (2 trials)

leucovorin (2 trials)

nivolumab (opdivo) (3 trials)

oxaliplatin (eloxatin) (2 trials)

paclitaxel (taxol) (2 trials)

palbociclib (ibrance) (1 trial)

pembrolizumab (keytruda) (8 trials)

pemetrexed (alimta) (2 trials)

plinabulin (1 trial)

ribociclib (kisqali) (1 trial)

rituximab (rituxan) (2 trials)

romidepsin (istodax) (1 trial)

sapanisertib (1 trial)

sorafenib (nexavar) (1 trial)

tak-659 (1 trial)

talazoparib (talzenna) (1 trial)

tamoxifen (nolvadex) (1 trial)

tazemetostat (1 trial)

telotristat ethyl (xermelo) (1 trial)

temozolomide (temodar) (1 trial)

Drugs in Phase 1 Trials (8)

avelumab (bavencio) (1 trial)

azacitidine (vidaza) (1 trial)

copanlisib (aliqopa) (1 trial)

eribulin (halaven) (1 trial)

everolimus (zortress) (1 trial)

ganitumab (1 trial)

gemtuzumab ozogamicin (mylotarg) (1 trial)

venetoclax (venclexta) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Breast Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Endometrial Neoplasms (Phase 2)

Esophageal Neoplasms (Phase 2)

Hodgkin Disease (Phase 2)

Kidney Neoplasms (Phase 2)

Leukemia (Phase 1)

Leukemia, Myeloid (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 2)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Peripheral (Phase 2)

Multiple Myeloma (Phase 2)

Myelodysplastic Syndromes (Phase 1)

Neoplasm Metastasis (Phase 1)

Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Preleukemia (Phase 1)

Salivary Gland Neoplasms (Phase 2)

Small Cell Lung Carcinoma (Phase 2)

Triple Negative Breast Neoplasms (Phase 2)

Uterine Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 33
  • # of Trial APIs: 49